TW321649B
(ja)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
US5932574A
(en)
*
|
1995-04-27 |
1999-08-03 |
Zeneca Limited |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
SI0892789T2
(sl)
|
1996-04-12 |
2010-03-31 |
Warner Lambert Co |
Ireverzibilni inhibitorji tirozin kinaz
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
ID19609A
(id)
*
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
US6310211B1
(en)
|
1996-09-10 |
2001-10-30 |
Pharmacia & Upjohn Company |
8-hydroxy-7-substituted quinolines as anti-viral agents
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
KR100567649B1
(ko)
*
|
1996-09-25 |
2006-04-05 |
아스트라제네카 유케이 리미티드 |
혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
JP2002512628A
(ja)
*
|
1997-06-13 |
2002-04-23 |
スージェン・インコーポレーテッド |
タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物
|
EP1005470B1
(en)
|
1997-08-22 |
2007-08-01 |
AstraZeneca AB |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9800575D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
US6313129B1
(en)
*
|
1998-08-21 |
2001-11-06 |
Hughes Institute |
Therapeutic compounds
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
JP2002527436A
(ja)
*
|
1998-10-08 |
2002-08-27 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
GB9822450D0
(en)
*
|
1998-10-14 |
1998-12-09 |
Smithkline Beecham Plc |
Medicaments
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
AU2437900A
(en)
*
|
1999-01-20 |
2000-08-07 |
Smithkline Beecham Plc |
Piperidinylquinolines as protein tyrosine kinase inhibitors
|
PL199802B1
(pl)
|
1999-02-10 |
2008-10-31 |
Astrazeneca Ab |
Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
TWI262914B
(en)
*
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
IL147280A0
(en)
*
|
1999-07-07 |
2002-08-14 |
Astrazeneca Uk Ltd |
Quinazoline derivatives
|
WO2001004111A1
(en)
*
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
CZ2002936A3
(cs)
|
1999-09-17 |
2002-10-16 |
Abbott Gmbh & Co. Kg |
Pyrazolopyrimidiny jako terapeutické prostředky
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
EP1676845B1
(en)
|
1999-11-05 |
2008-06-11 |
AstraZeneca AB |
New quinazoline derivatives
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
DE60112268T2
(de)
|
2000-03-06 |
2006-05-24 |
Astrazeneca Ab |
Verwendung von quinazolinderivate als inhibitoren der angiogenese
|
AU2001246850A1
(en)
*
|
2000-04-06 |
2001-10-23 |
Kyowa Hakko Kogyo Co. Ltd. |
Diagnostics and remedies for rheumatoid arthritis
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
ATE413394T1
(de)
|
2000-06-24 |
2008-11-15 |
Astrazeneca Ab |
Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
|
US6919338B2
(en)
|
2000-06-28 |
2005-07-19 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
|
WO2002008224A1
(en)
|
2000-07-26 |
2002-01-31 |
Smithkline Beecham P.L.C. |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
|
JP2004505964A
(ja)
|
2000-08-09 |
2004-02-26 |
アストラゼネカ アクチボラグ |
Vegf阻害活性を有するキノリン誘導体
|
WO2002016352A1
(en)
|
2000-08-21 |
2002-02-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2334641T3
(es)
|
2000-09-01 |
2010-03-15 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados aza heterociclicos y su uso terapeutico.
|
SG174632A1
(en)
|
2000-09-11 |
2011-10-28 |
Novartis Vaccines & Diagnostic |
Quinolinone derivatives
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
US6849625B2
(en)
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
EP1332141A1
(en)
*
|
2000-10-25 |
2003-08-06 |
AstraZeneca AB |
Quinazoline derivatives
|
DE60144284D1
(de)
|
2000-11-01 |
2011-05-05 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
WO2002036570A1
(en)
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
MY142915A
(en)
*
|
2001-03-23 |
2011-01-31 |
Bayer Healthcare Llc |
Rho-kinase inhibitors
|
JP4329003B2
(ja)
*
|
2001-03-23 |
2009-09-09 |
バイエル コーポレイション |
Rhoキナーゼ阻害剤
|
ATE449763T1
(de)
|
2001-04-16 |
2009-12-15 |
Eisai R&D Man Co Ltd |
1h-indazolverbindungen die jnk hemmen
|
JP4307843B2
(ja)
|
2001-04-19 |
2009-08-05 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
KR100810468B1
(ko)
*
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체
|
CN100343238C
(zh)
*
|
2001-11-03 |
2007-10-17 |
阿斯特拉曾尼卡有限公司 |
用作抗肿瘤药物的喹唑啉衍生物
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
UA82058C2
(uk)
|
2001-12-24 |
2008-03-11 |
Астразенека Аб |
Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
|
WO2003059913A1
(en)
|
2002-01-10 |
2003-07-24 |
Bayer Healthcare Ag |
Roh-kinase inhibitors
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
CA2473910C
(en)
|
2002-01-23 |
2011-03-15 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
WO2003064431A2
(en)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
WO2003064421A1
(en)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Aminopiperidine derivatives
|
AU2003202094B2
(en)
*
|
2002-02-01 |
2009-10-08 |
Astrazeneca Ab |
Quinazoline compounds
|
PT1478358E
(pt)
|
2002-02-11 |
2013-09-11 |
Bayer Healthcare Llc |
Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
|
TW200302722A
(en)
*
|
2002-02-13 |
2003-08-16 |
Astrazeneca Ab |
Therapeutic agents
|
US7645878B2
(en)
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE60327323D1
(de)
|
2002-07-09 |
2009-06-04 |
Astrazeneca Ab |
Chinazoline derivative und ihre anwendung in der krebsbehandlung
|
AU2003249212C1
(en)
|
2002-07-15 |
2011-10-27 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
DE60313339T2
(de)
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
EP1539754A4
(en)
|
2002-08-23 |
2009-02-25 |
Novartis Vaccines & Diagnostic |
BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
|
DE60318089T2
(de)
|
2002-10-09 |
2008-12-04 |
Critical Outcome Technologies, Inc. |
Protein-tyrosine-kinase-inhibitoren
|
WO2004041277A1
(en)
*
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
PT1562955E
(pt)
*
|
2002-11-04 |
2008-05-05 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores da scr tirosina-cinase
|
CN100354278C
(zh)
*
|
2002-11-04 |
2007-12-12 |
阿斯利康(瑞典)有限公司 |
作为src酪氨酸激酶抑制剂的喹唑啉衍生物
|
KR20050075005A
(ko)
|
2002-11-13 |
2005-07-19 |
카이론 코포레이션 |
암을 치료하는 방법 및 관련 방법
|
DE10260730A1
(de)
*
|
2002-12-23 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
|
US7429597B2
(en)
|
2002-12-23 |
2008-09-30 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
|
DE60315892T2
(de)
|
2002-12-24 |
2008-08-14 |
Astrazeneca Ab |
Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
|
GB0307333D0
(en)
*
|
2003-03-29 |
2003-05-07 |
Astrazeneca Ab |
Therapeutic agent
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2007511203A
(ja)
|
2003-05-20 |
2007-05-10 |
バイエル、ファーマシューテイカルズ、コーポレイション |
キナーゼ阻害活性を有するジアリール尿素
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318422D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
EP1667991B1
(en)
|
2003-09-16 |
2008-05-14 |
Astrazeneca AB |
Quinazoline derivatives as tyrosine kinase inhibitors
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2371383T3
(es)
|
2003-09-26 |
2011-12-30 |
Exelixis, Inc. |
N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN1890234A
(zh)
|
2003-12-23 |
2007-01-03 |
辉瑞大药厂 |
新颖的喹啉衍生物
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
EA011402B1
(ru)
|
2004-01-23 |
2009-02-27 |
Эмджен Инк. |
Азотсодержащие гетероциклические производные и их фармацевтические применения
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
BRPI0507891A
(pt)
|
2004-02-20 |
2007-07-24 |
Chiron Corp |
modulação dos processos inflamatório e metastático
|
NZ550796A
(en)
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
US7452887B2
(en)
|
2004-06-04 |
2008-11-18 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
BRPI0511741A
(pt)
*
|
2004-06-04 |
2008-01-02 |
Astrazeneca Ab |
derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
CN101072758B
(zh)
|
2004-10-12 |
2013-07-31 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
MX2007006230A
(es)
|
2004-11-30 |
2007-07-25 |
Amgen Inc |
Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
US7358256B2
(en)
|
2005-03-28 |
2008-04-15 |
Bristol-Myers Squibb Company |
ATP competitive kinase inhibitors
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
ES2440799T3
(es)
|
2005-05-13 |
2014-01-30 |
Novartis Ag |
Métodos para tratar cáncer resistente a los fármacos
|
US8222413B2
(en)
|
2005-05-17 |
2012-07-17 |
Novartis Ag |
Methods for synthesizing heterocyclic compounds
|
RU2425041C2
(ru)
|
2005-05-23 |
2011-07-27 |
Новартис Аг |
Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
|
CA2615380A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Schering Corporation |
Quinazoline derivatives useful in cancer treatment
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
CN102633783A
(zh)
|
2006-02-10 |
2012-08-15 |
转化技术制药公司 |
作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
ES2556173T3
(es)
|
2006-05-18 |
2016-01-13 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral para un cáncer de tiroides
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
ATE547415T1
(de)
*
|
2007-09-21 |
2012-03-15 |
Janssen Pharmaceutica Nv |
Inhibitoren der wechselwirkung zwischen mdm2 und p53
|
CA2703257C
(en)
|
2007-10-29 |
2013-02-19 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
EP2220054A2
(en)
|
2007-10-29 |
2010-08-25 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
WO2009079797A1
(en)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
WO2009098061A1
(de)
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
WO2009138781A1
(en)
|
2008-05-13 |
2009-11-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
CN110818633A
(zh)
|
2009-01-16 |
2020-02-21 |
埃克塞里艾克西斯公司 |
一种苹果酸盐及其晶型
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
LT3575288T
(lt)
|
2009-09-03 |
2021-12-10 |
Bristol-Myers Squibb Company |
Chinazolinai kaip kalio jonų kanalų inhibitoriai
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
BR112013002212A2
(pt)
*
|
2010-07-29 |
2017-09-26 |
Merck Patent Gmbh |
carboxamidas aza-heterocíclicas de aminas cíclicas
|
BR112013022552B1
(pt)
|
2011-03-04 |
2021-11-23 |
Newgen Therapeutics, Inc |
Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
CN102942561A
(zh)
*
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-氨基喹唑啉杂环化合物及其用途
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
BR112015020139A2
(pt)
|
2013-02-20 |
2017-07-18 |
Kala Pharmaceuticals Inc |
compostos terapêuticos e usos dos mesmos
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
JP6268276B2
(ja)
|
2013-04-04 |
2018-01-24 |
ヤンセン ファーマシューティカ エヌ.ベー. |
PERK阻害剤としての新規なN(2,3−ジヒドロ−1H−ピロロ[2,3−b]ピリジン−5−イル)−4−キナゾリンアミン誘導体およびN−(2,3−ジヒドロ−1H−インドール−5−イル)−4−キナゾリンアミン誘導体
|
KR102204279B1
(ko)
|
2013-05-14 |
2021-01-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
|
TW201534597A
(zh)
*
|
2013-06-20 |
2015-09-16 |
Ab Science |
作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
|
ME02860B
(me)
|
2013-09-16 |
2018-04-20 |
Astrazeneca Ab |
Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
|
KR20160099084A
(ko)
|
2013-11-01 |
2016-08-19 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정질 형태 및 그의 용도
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EA032559B1
(ru)
*
|
2014-04-04 |
2019-06-28 |
Пфайзер Инк. |
Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
|
RS63559B1
(sr)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Man Co Ltd |
Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
CN104725364B
(zh)
*
|
2015-03-12 |
2017-09-15 |
江苏省中国科学院植物研究所 |
6,7‑二甲氧基‑喹唑啉‑4‑胺衍生物、其制备方法及医药用途
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
JP6740354B2
(ja)
|
2015-10-05 |
2020-08-12 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
|
CN106045980B
(zh)
*
|
2016-06-03 |
2017-11-03 |
江苏开放大学 |
一种喹唑啉衍生物及其制备方法
|
AU2017324716B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EP3509422A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
CN109688818A
(zh)
|
2016-09-08 |
2019-04-26 |
卡拉制药公司 |
治疗化合物的晶型及其用途
|
RU2769694C2
(ru)
|
2017-04-27 |
2022-04-05 |
Астразенека Аб |
C5-Анилинохиназолиновые соединения и их использование в лечении рака
|
CA3059660A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Astrazeneca Ab |
Phenoxyquinazoline compounds and their use in treating cancer
|
CN111868039A
(zh)
*
|
2017-09-26 |
2020-10-30 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
FR3080620B1
(fr)
*
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
|